Commentary

Video

The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL

Author(s):

Javier Pinilla, MD, PhD,Talha Badar, MBBS, MD

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.

Related Videos
Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.
Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
Floortje J. Backes, MD, discusses data for mirvatuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer
Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.
Floortje J Backes, MD, discusses how mirvatuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024..
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.
Related Content
Acute Myeloid Leukemia | © Nittaya – stock.adobe.com
February 6th 2025

Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML

Roxana S. Dronca, MD, professor, oncology, consultant, Division of Hematology/Oncology, Department of Internal Medicine, director, Mayo Clinic Comprehensive Cancer Center
January 20th 2025

FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.
February 2nd 2025

Five Under 5: Top Oncology Videos for the Week of 1/26

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

FDA
January 30th 2025

MB-105 Receives Orphan Drug Designation in Relapsed/Refractory CD5+ T-Cell Lymphoma

B-ALL | © Свет Лана – stock.adobe.com
January 30th 2025

European Commission Approves Blinatumomab Consolidation in Newly Diagnosed CD19+ B-ALL